← Back to Search

Virus Therapy

Ebola Vaccine for Occupational Exposure Prevention

Phase 2

Waitlist Available

Led By Richard T Davey, M.D.

Research Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

percutaneous contraceptive patches

Adults age greater than equal to 18 years.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up month 36

Awards & highlights

Study Summary

This trial is testing an Ebola vaccine to see if it is effective in preventing the disease. Healthy adults who are at risk of exposure to the virus will be given the vaccine and monitored for side effects. There will be follow-up visits over the course of 3 years.

Who is the study for?

Healthy adults over 18 at risk of Ebola exposure through work, willing to minimize blood and body fluid contact with others for 14 days post-vaccination. They must agree not to take other investigational drugs or donate blood for a year after vaccination, use effective contraception methods, and be non-pregnant and non-breastfeeding.Check my eligibility

What is being tested?

The trial is testing the rVSV-Zebov GP vaccine's long-term effectiveness in preventing Ebola when given before exposure. Participants will receive an initial shot followed by monitoring visits over 36 months; half will get a booster dose at month 18.See study design

What are the potential side effects?

Possible side effects include reactions at the injection site, flu-like symptoms such as fever or fatigue, muscle pain, headache, and joint pain. Participants are asked to record any symptoms following vaccination in a provided diary card.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I use skin patches for birth control.

Select...

I am 18 years old or older.

Select...

I am currently using oral contraceptives.

Select...

I am currently using injectable birth control.

Select...

I have an implant of etonogestrel or levonorgestrel.

Select...

I am using an estrogen vaginal ring.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ month 36

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~month 36

This trial's timeline: 3 weeks for screening, Varies for treatment, and month 36 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Comparison of antibody titer levels between the boosted vs non-boosted groups

Trial Design

2Treatment groups

Experimental Treatment

Group I: Non-boosted GroupExperimental Treatment1 Intervention

Group randomized to 'no booster' at Month 18

Group II: Boosted GroupExperimental Treatment1 Intervention

Group randomized at Month 18 to receive booster vaccination

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Institute of Allergy and Infectious Diseases (NIAID)Lead Sponsor

3,268 Previous Clinical Trials

5,481,033 Total Patients Enrolled

Richard T Davey, M.D.Principal InvestigatorNational Institute of Allergy and Infectious Diseases (NIAID)

12 Previous Clinical Trials

6,114 Total Patients Enrolled

Media Library

rVSV[Delta]G-ZEBOV-GP (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02788227 — Phase 2

Healthy Subjects Research Study Groups: Boosted Group, Non-boosted Group

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In how many different places is this experiment being conducted currently?

"A few of the 8 locations where this study is enrolling patients are Hope Clinic - Emory Vaccine Ctr in Decatur, Maryland, National Institutes of Health Clinical Center, 9000 Rockville Pike in Bethesda, Massachusetts, and Boston Medical Center in Boston, Texas."

Answered by AI

What are the side-effects of rVSV-Zebov GP vaccine?

"While there is some evidence that the rVSV-Zebov GP vaccine is safe, it only received a score of 2 because, as this is only a Phase 2 trial, there is no data yet supporting its efficacy."

Answered by AI

Are there still opportunities for people to participate in this research project?

"The clinical trial you're referring to is no longer recruiting patients, based on the information found on clinicaltrials.gov. This study was posted on October 14th 2016 and last edited November 16th 2020. However, there are 940 other studies that are still recruiting patients."

Answered by AI